BioTelemetry (BEAT) was Reiterated by The Benchmark Company to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 25 from a previous price target of $20 . The Benchmark Company advised their investors in a research report released on Aug 3, 2016.
On the company’s financial health, BioTelemetry reported $0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.17. The company had revenue of $52.68 million for the quarter, compared to analysts expectations of $50.27 million. The company’s revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 EPS.
BioTelemetry opened for trading at $20.05 and hit $20.05 on the upside on Tusday, eventually ending the session at $19.5, with a gain of 1.62% or 0.31 points. The heightened volatility saw the trading volume jump to 8,39,136 shares. Company has a market cap of $544 M.